WO2014207664A2 - Stable pharmaceutical composition of asenapine - Google Patents

Stable pharmaceutical composition of asenapine Download PDF

Info

Publication number
WO2014207664A2
WO2014207664A2 PCT/IB2014/062575 IB2014062575W WO2014207664A2 WO 2014207664 A2 WO2014207664 A2 WO 2014207664A2 IB 2014062575 W IB2014062575 W IB 2014062575W WO 2014207664 A2 WO2014207664 A2 WO 2014207664A2
Authority
WO
WIPO (PCT)
Prior art keywords
asenapine
pharmaceutical composition
stable pharmaceutical
water soluble
pharmaceutically acceptable
Prior art date
Application number
PCT/IB2014/062575
Other languages
English (en)
French (fr)
Other versions
WO2014207664A3 (en
Inventor
Veerababu Ramabrahmmam Taduri
Viral Ramesh VAIDYA
Jigar Rameshchandra LALANI
Original Assignee
Alembic Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alembic Pharmaceuticals Limited filed Critical Alembic Pharmaceuticals Limited
Publication of WO2014207664A2 publication Critical patent/WO2014207664A2/en
Publication of WO2014207664A3 publication Critical patent/WO2014207664A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Definitions

  • the present invention relates to a stable pharmaceutical composition for sublingual and/or buccal administration of Asenapine and process for preparation of said pharmaceutical composition.
  • Asenapine is an antipsychotic drug used for the treatment of schizophrenia and bipolar and acute mania associated with bipolar disorder. Asenapine in form of maleate salt (Asenapine Maleate) is available in market for such treatment under the brand name of Saphris®, Sycrest®.
  • Asenapine i.e. trans-5-Chloro-2,3,3a, 12b-tetrahydro-2-methyl-IH- dibenz[2,3:6, 7]oxepino[4,5-c]pyrrole
  • Asenapine is a pyrrolidino tetracyclic compound with potent dopamine, serotonin and adrenergic antagonist properties.
  • the compound has high affinity for dopamine 1 , 2, 3 and 4 receptors, and for serotonin 2A, 2C, 1A, 6 and 7 receptors as well as noradrenaline- 1 and 2 receptor types.
  • US4145434 discloses about Asenapine and its salt and method of synthesis of Asenapine and its maleate salt. Asenapine is characterized by low bioavailability and show extensive first pass metabolism when taken up via the gastrointestinal tract.
  • US5763476 discloses sublingual or buccal tablet that contains 5 mg or 10 mg of Asenapine or salt thereof, mannitol and partially hydrolysed gelatin prepared by freeze- drying. US5763476 is silent about method other than freeze-drying to prepare said composition. However, a significant drawback of this freeze-drying process is that it leads to an expensive production, in particular due to the long duration of each freeze drying cycle (normally 24 to 48 hours) and the necessity to use sophisticated equipment for carrying out the process. Moreover, freeze-dried compositions are generally not stable enough to be easily handled by the modern high-speed packaging machines.
  • US7741358, EP1710245 and WO 2006106135 disclose a pharmaceutical composition
  • a pharmaceutical composition comprising the orthorhombic form (form-L, having melting point in range of 138-142 °C) of asenapine Maleate prepared by freez drying method and US 7741358 also discloses about monoclinic form (Form-H having melting point in range of 141- 145°C). It is also mentioned that the reason for the use of form L - despite its lower solubility - is that for sublingual or buccal administration, a drug substance with a small particle size is desired (see page 2, lines 8 to 16 of WO2006/106135 A1 ).
  • WO2006/106135 A1 discloses that only form L can be reproducibly obtained by micronisation in high polymorph purity whereas micronisation of monoclinic form H resulted in a non reproducible product (page 2, lines 22 to 32 and examples 9 and 10 of WO2006/106135 A1 ).
  • US20080090892 discloses the preparation of Amorphous Asenapine maleate by using spray drying method and freeze drying method. US20080090892 further discloses the use of other excipients to prepare amorphous asenapine maleate and also mentioned that as per the invention of US20080090892, Asenapine maleate is at least 50%, 75%, 90%, 95%, or 99% amorphous, based on the total weight of the compound. Hence, the crystalline asenapine maleate might be present in the final composition. US20080090892 also disclose the use of different pharmaceutical excipient disintegrants, surfactant, glidants, lubricants, binding agent, diluents, flavorant and sweetener for preparation of tablet dosage form.
  • WO201 1 159903A1 discloses about a monoclinic form of asenapine maleate, which is stable to micronization, and processes for preparation thereof.
  • WO201 1 159903A1 also taught about pharmaceutical compositions comprising a microcrystalline monoclinic form of asenapine maieate, using at least one pharmaceutically acceptable excipient.
  • WO2012066565A2 discloses about substantially pure monoclinic form of asenapine maleate having particle size of d95 less than about 100 microns and process for preparation of same.
  • WO2012066565A2 mentioned that "The particle size of the drug substance influences biopharmaceutical properties of the drug product. For example, the particle size of the drug substance affects drug product manufacturing and dissolution and hence its bioavailability. Since asenapine dissolves in the saliva the particle size is important. When drug substance particles are small, it takes only short periods of time to achieve high concentrations. From this perspective small particles are preferred.
  • WO2012066565A2 also discloses "process for preparing amorphous asenapine maleate comprising slurrying asenapine maleate in a solvent selected from a group consisting of organic solvent such as aromatic hydrocarbons, glycerol, tetrahydrofuran, esters, ethers, ketones, alcohols and water or a mixture thereof.
  • a solvent selected from a group consisting of organic solvent such as aromatic hydrocarbons, glycerol, tetrahydrofuran, esters, ethers, ketones, alcohols and water or a mixture thereof.
  • Another embodiment of the invention encompasses a process for preparing amorphous asenapine maleate comprising spray drying a solution of asenapine maleate in alcoholic solvent" and preparation of pharmaceutical composition containing substantially pure monoclinic form of asenapine maleate having particle size of d95 less than about 100 microns or amorphous asenapine maleate.
  • WO2012123325A1 discloses about new crystalline polymorphic forms of asenapine maleate (Form-M and Form-T), which can be micronized to a suitable particle size without a substantial conversion into the orthorhombic form (form-L) and which show an improved water solubility when compared the orthorhombic form (Form- L) and the monoclinic form (Form-H).
  • WO2012123325A1 also revealed that the crystalline asenapine maleate Form-M and Form-T show excellent properties in term of stability, bioavailability, solubility and flowability, which contributes to a successful drug development and that these crystalline polymorphic Form-M and Form-T are suitable to be formulated, for example in the form of tablets for sublingual or buccal administration.
  • WO20121 14325A1 discloses about a new crystalline form and a amorphous form of asenapine maleate.
  • the new crystalline form (Form II) having good bioavailability as well as adequate stability characteristics like less hygroscopic, has improved chemical stability at high humidity-conditions (75% RH) and shows enhanced aqueous solubility as compared to the known amorphous asenapine maleate of US 2008/0090892 enabling their incorporation into a variety of solid dosage forms (e.g. sub-lingual tablets).
  • WO20121 14325A1 also taught about amorphous asenapine maleate having average particle size about 25-50 ⁇ with D90 of about 60-70 ⁇ and use of vaccum drying, melting method and freeze drying method for preparation of amorphous asenapine maleate and general disclosure about preparation of pharmaceutical composition.
  • WO2012080195A2 discloses anhydrous polymorphic Form G, G1 and G2 of asenapine maleate that are stable at room temperature, reproducible and suitable for pharmaceutical dosage form and general disclosure about use of said polymorphic form for preparation of pharmaceutical composition.
  • WO2012038975A2 discloses about stable crystalline Form-H of Asenapine maleate that does not convert in to crystalline Form-L during micronisation or its storage after micronisation. WO2012038975A2 further discloses about orally disintegrating tablet having low friability, dispersion time of 35-60 seconds, 80-100% dissolution rate within 5 to 10 minutes comprising essentially of F-Melt and use of simple wet granulation technique to prepare said tablet wherein asenapine maleate is in crystalline or amorphous form.
  • asenapine maleate according to invention having purity greater than 99% by HPLC and the level of different impurities including N-Oxide impurity are well controlled with in the limits as per the ICH guidelines.
  • WO2012156676 A1 discloses about a stable monoclinic crystalline form of asenapine maleate having low particle size (d90 of 40 ⁇ or less) which avoids the need to use a micronisation process and discloses about different pharmaceutical dosage form comprises of stable monoclinic crystalline form of asenapine maleate.
  • WO2012156677A1 discloses about a stable monoclinic crystalline form of asenapine maleate having low particle size (d90 equal to or below 40 ⁇ ) prepared by using gas jet milling method under specific micronisation condition of temperature and pressure and also discloses that the said monoclinic crystalline form may contains orthorhombic form less than 1 % by weight.
  • WO2012150538A1 relates to asenapine phosphate and a novel monoclinic crystalline form of asenapine maleate characterized by specific XRPD, IR and DSC (132.8 °C) which is differs from the orthorhombic and monoclinic polymorphic form disclosed in US 7741358.
  • WO2012150538A1 discloses that the novel monoclinic crystalline form having chemico-physical and biopharmaceutical property such as stability, dissolution rate and bioavailability and preparation of pharmaceutical composition comprises of said crystalline form.
  • WO2013024492 A2 taught about process for preparation of asenapine or its acid addition salt, asenapine sulphate, novel crystalline form of asenapine sulphate and asenapine maleate.
  • WO2013024492A2 also discloses about co-precipitate of amorphous form of asenapine sulphate and asenapine maleate and process for preparation of co-precipitate wherein solution of asenapine sulphate or maleate and pharmaceutical excipient is prepared and solvent is removed from said solution to obtain solid residue or co-precipitate.
  • the pharmaceutical excipient(s) used for preparation of co-precipitate is selected form polyvinylpyrrolidone, gum, cellulose derivatives, cyclodextrins, gelatins, hypromellose phthalate, sugar and polyvinyl alcohols.
  • WO2013041604A1 discloses about crystalline Form-S of Asenapine Maleate and use of Form S as a starting material for preparation of crystalline monoclinic form of Asenapine Maleate having particle size distribution d95 at 50 ⁇ preferably at most 30 ⁇ having less than 10% orthorhombic crystalline form optionally less than 5% or no detectable amount.
  • WO2013041604A1 also discloses use of monoclinic form of Asenapine maleate for sublingual or buccal formulation.
  • WO2013041435A1 discloses about compressed dosage form of asenapine maleate for sublingual or buccal administration comprises of microcrystalline monoclinic asenapine maleate (characterized by a d95 of less than 75 ⁇ , and contains less than 5 % w/w of asenapine maleate in the crystalline orthorhombic form), said dosage form should not comprises a significant amount of amorphous asenapine maleate.
  • amorphous asenapine maleate is hygroscopic and less stable than the crystalline forms.
  • the present invention provide a novel composition and process for preparation of a stable pharmaceutical composition of asenapine or acceptable salt thereof having improved bioavailability or is bioequivalent to marketed product, wherein asenapine or pharmaceutical acceptable salt thereof can be used in any form i.e. any crystalline or amorphous form without any specific particle size. Further, the present invention provides a stable pharmaceutical composition wherein the level of impurity in final dosage form is low or negligible.
  • An object of the present invention is to provide a stable pharmaceutical composition of asenapine or pharmaceutical acceptable salt thereof for sublingual or buccal administration having improved bioavailability or is bioequivalent to marketed product.
  • a stable pharmaceutical composition which meets the above requirement, has been found in the form of pharmaceutical composition comprising asenapine or pharmaceutically acceptable salt thereof, antioxidant, water soluble diluent, water soluble/swellable binder, disintegrant and optionally one or more surfactant and/or one or more pharmaceutically acceptable excipient.
  • asenapine is as base or pharmaceutically acceptable salt of asenapine selected from maleate, palmitate, pamoate, acetate, benzoate, hemi-pamaote, naphtoate, fumarate, succinate, oxalate, hydrochloride, hydrobromide, phosphate or sulphate.
  • asenapine is used in the form of maleate salt i.e. asenapine maleate.
  • asenapine used for the purpose of the invention is asenapine maleate in polymorphic form know in US7741358/EP1710245/WO2006106135 (monoclinic form (Form-H) or orthorhombic form (Form-L)), amorphous form, WO2012123325A1 (Form M or form T), WO20121 14325A1 (Form II), WO2012080195A2 (Anhydrous polymorphic Form G, G1 and G2), WO2012150538A1 , WO2013024492 A2, WO2013041604A1 (From-S), CN102952144A (Form-A or Form B) or any polymorphic form of asenapine maleate know to the person skilled in the art as a input material for preparation of pharmaceutical composition as per the invention.
  • asenapine maleate whether in amorphous or polymorphic form as mentioned above is used without any limitation of particle size or of any particle size as a input material for the preparation of pharmaceutical composition as per the invention.
  • asenapine maleate is monoclinic crystalline form (Form-H) without any limitation of particle size or of any particle size used as a input material for the preparation of pharmaceutical composition as per the invention. Further, during experimentation, the following impurities were found in active substance or during preparation of pharmaceutical composition.
  • level of impurity could be reduced or prevented from increasing in the final composition by using antioxidant during preparation of pharmaceutical composition of asenapine or pharmaceutically acceptable salt thereof.
  • a stable pharmaceutical composition comprising asenapine or pharmaceutically acceptable salt thereof and antioxidant.
  • a stable pharmaceutical composition comprising asenapine or pharmaceutically acceptable salt thereof, antioxidant, water soluble diluent, water soluble/swellable binder, disintegrant and one or more pharmaceutically acceptable excipient.
  • a stable pharmaceutical composition comprising asenapine or pharmaceutically acceptable salt thereof, antioxidant, water soluble diluent, water soluble/swellable binder, disintegrant and optionally one or more surfactant and/or one or more pharmaceutically acceptable excipient.
  • a stable pharmaceutical composition consisting essentially of asenapine or pharmaceutically acceptable salt thereof, antioxidant and one or more pharmaceutically acceptable excipient.
  • Another aspect of the invention is to provide a pharmaceutical composition of asenapine or pharmaceutical acceptable salt thereof for sublingual or buccal administration having improved bioavailability or is bioequivalent to marketed product.
  • Another aspect of the invention is to provide, a rapidly dissolving stable pharmaceutical composition of asenapine or pharmaceutically acceptable salt thereof.
  • a stable pharmaceutical composition as per the present invention release at least about 65% of asenapine within 5 min.
  • a stable pharmaceutical composition as per the present invention release at least about 80% of asenapine within 15 min.
  • Another aspect of the invention is to provide, a stable pharmaceutical composition of asenapine or pharmaceutically acceptable salt thereof wherein total impurity is less than 0.2% and N-oxide impurity is less than 0.04%.
  • Another aspect of the invention is to provide, a stable pharmaceutical composition of asenapine or pharmaceutically acceptable salt thereof wherein total impurity is less than 0.45% and N-oxide impurity is less than 0.3% after 3 month accelerated stability study.
  • a stable pharmaceutical composition of asenapine or pharmaceutically acceptable salt thereof with above mentioned level of impurity is achieved by using antioxidant during preparation of pharmaceutical composition.
  • an antioxidant is at least about 0.10% by weight of total composition, more preferably at least about 0.12% of total composition.
  • an antioxidant is in range of 0.10 to 0.25 % of total composition.
  • antioxidant is selected from, but not limited to Butylated hydroxytoluene (BHT) and Butylated hydroxyanisole (BHA) or mixture thereof.
  • water- soluble/swellable excipients to prepare pharmaceutical composition for sublingual or buccal administration of Asenapine or pharmaceutically acceptable salt thereof.
  • the use of water soluble/swellable excipients optionally with or without surfactant helps to improve the dissolution and ultimately bioavailability or to prepare bioequivalent pharmaceutical composition of Asenapine to marketed product.
  • a stable pharmaceutical composition of Asenapine or pharmaceutically acceptable salt thereof comprises water soluble diluent, water soluble/swellable binder, disintegrant along with anti-oxidants optionally one or more surfactant and/or one or more pharmaceutically acceptable excipients.
  • a water soluble diluent is at least about 50% by weight of total composition.
  • water soluble diluent is selected from, but not limited to lactose, mannitol, xylitol, sorbitol, calcium sulfate dihydrate, inositol, dextrin, calcium sulfate anhydrous, fructose, kaolin, sugar compressible, sucrose, lactitol, dextrates, confectioner's sugar, sucrose, sodium chloride, dextrose, cyclodextrin or any combination thereof.
  • water soluble diluent is selected from, but not limited to lactose, mannitol, xylitol, sorbitol or any combination thereof.
  • a water soluble/swellable binder is about at least about 2.5% by weight of total composition
  • water soluble/swellable binder is selected from but not limited to polyvinyl pyrrolidone, starch, gelatin, sucrose, lactose, cellulose derivative like Hydroxypropyl methyl cellulose, Hydroxypropyl cellulose, low substituted hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxyl methyl cellulose or mixture of any thereof.
  • water soluble/swellable binder is selected from polyvinyl pyrrolidone, hydroxypropyl cellulose, low substituted hydroxypropyl cellulose or mixture of thereof.
  • a disintegrant is at least about 15% by weight of total composition.
  • disintegrant is selected form, but not limited to cross-linked carboxymethylcellulose sodium, cross-linked polyvinylpyrrolidone, pregelatinized starch, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, sodium alginate, sodium starch glycolate, crospovidone, croscarmellose sodium and low substituted hydroxyl propyl cellulose or mixture thereof.
  • disintegrant is used intra- granular and extragranular in the pharmaceutical composition.
  • intra-granular and extragranular disintegrant is same or different.
  • one or more pharmaceutically acceptable excipient are selected from, but not limited to lubricant, glidant, sweeteners, flavoring agent, coloring agent, antiadherents and mixture thereof.
  • Other excipients known in the field of pharmaceutical composition may be also used.
  • a surfactant is at least about 0.4% by weight of total composition.
  • one or more surfactant is selected from, but not limited to ionic, nonionic.
  • Ionic surfactants may include one or more of anionic, cationic or zwitterionic surfactants.
  • anionic surfactant is selected from, but not limited to one or more of sodium lauryl sulphate, sodium dodecyl sulphate, ammonium lauryl sulphate, alkyl benzene sulfonate, perfluorooctanoate, perfluorooctanesulfonate etc.;
  • cationic surfactants may be selected from benzalkonium chloride, benzethonium chloride, polyethoxylated tallow amine, cetyl pyridinium chloride, cetyl trimethylammonium bromide, hexadecyl trimethyl ammonium bromide and other alkyltrimethyl ammonium salts etc.; or amphoteric surfactants may be selected from dodecyl betaine, cocamidopropyl betaine, cocoampho glycinate etc.
  • the ionic surfactants may also include alkylammonium salts; fusidic acid salts; fatty acid derivatives of amino acids, oligopeptides, and polypeptides; glyceride derivatives of amino acids, oligopeptides, and polypeptides; lecithins and hydrogenated lecithins; lysolecithins and hydrogenated lysolecithins; phospholipids and derivatives thereof; lysophospholipids and derivatives thereof; carnitine fatty acid ester salts; salts of alkylsulfates; fatty acid salts; acyl lactylates; mono- and di-acetylated tartaric acid esters of mono- and di-glycerides; succinylated mono- and di-glycerides; citric acid esters of mono- and di-glycerides, and the like.
  • cationic surfactants is selected from, but not limited to one or more of quaternary ammonium compounds, such as benzalkonium chloride, cetyl trimethyl ammonium bromide and dodecyl dimethyl ammonium bromide, hexadecyl (cetyl) trimethylammonium bromide, dodecyl pyridinium chloride, lauryl dimethyl benzyl ammonium chloride, acyl carnitine hydrochlorides, alkyl pyridinium halides, dodecylamine hydrochloride, and the like.
  • quaternary ammonium compounds such as benzalkonium chloride, cetyl trimethyl ammonium bromide and dodecyl dimethyl ammonium bromide, hexadecyl (cetyl) trimethylammonium bromide, dodecyl pyridinium chloride, lauryl dimethyl benzyl ammonium chloride, acyl carni
  • zwitterionic surfactants is selected from, but not limited to one or more of alkyl betaines, alkyl amidopropyl betaines, alkyl sulphobetaines, alkyl glycinates, alkyl carboxyglyci nates, alkyl amphopropionates, alkyl amidopropyl hydroxysultaines, acyl taurates and acyl glutamates wherein the alkyl and acyl groups have from 8 to 18 carbon atoms such as cocamidopropyl betaine, sodium cocoamphoacetate, cocamidopropyl hydroxysultaine, and sodium cocamphopropionate, and the like.
  • non-ionic surfactant is selected from, but not limited to one or more of ethyleneoxide/propyleneoxide copolymers referred to hereinbelow as poloxamers, such as poloxamer 124 sold under the brand name Synperonic.RTM. PE/L44; poloxamer 188 sold under the brand name Pluronic.RTM. F68 or Synperonic.RTM. PE/F68; poloxamer 237 sold under the brand name Pluronic.RTM. F87 or Synperonic.RTM. PE/F87; poloxamer 338 sold under the brand name Synperonic.RTM. PE/F108 or poloxamer 407 sold under the brand name Pluronic.RTM.
  • poloxamers such as poloxamer 124 sold under the brand name Synperonic.RTM. PE/L44; poloxamer 188 sold under the brand name Pluronic.RTM. F68 or Synperonic.RTM. PE/F68; poloxamer 237 sold under the brand name Pl
  • F127 Synperonic.RTM. PE/F127 or Lutrol.RTM. F127.
  • polyethoxylated castor oils such as those sold under the brand name Cremophor.RTM. RH40.
  • ethoxylated polysorbates such as polysorbate 20, polysorbate 40, polysorbate 60 and polysorbate 80 sold respectively under the brand names Tween.RTM. 20, Tween.RTM. 40, Tween.RTM. 60 and Tween.RTM. 80. or alternatively polyethylene hydroxystearates such as polyethylene hydroxystearate 660 sold under the brand name Solutol.RTM. HS15.
  • a stable pharmaceutical composition comprising Asenapine or pharmaceutically acceptable salt thereof and an antioxidant selected from Butylated hydroxytoluene and Butylated hydroxyanisole or mixture thereof
  • a stable pharmaceutical composition comprising Asenapine or pharmaceutically acceptable salt thereof, an antioxidant is at least about 0.10%, a water soluble diluent is at least about 50%, a water soluble/swellable binder is at least about 2.5%, disintegrant is at least about 15% and optionally surfactant is at least about 0.4% by weight of total composition.
  • a stable pharmaceutical composition comprising Asenapine maleate, an antioxidant is selected from Butylated hydroxytoluene, Butylated hydroxyanisole or combination thereof, a water soluble diluent is selected from lactose, mannitol, xylitol, and sorbitol, a water soluble/sellable binder is selected from polyvinylpyrrolidone and hydroxypropyl cellulose and disintegrant.
  • a stable pharmaceutical composition comprising Asenapine maleate, butylated hydroxytoluene butylated hydroxyanisole, mannitol, polyvinylpyrrolidone or hydroxypropyl cellulose, low-substituted hydroxyproopyl cellulose and optionally polysorbate 80.
  • composition of asenapine or pharmaceutical acceptable salt thereof for sublingual or buccal administration having improved bioavailability or is bioequivalent to marketed product.
  • inventive process of the invention offer advantage compared to prior art process to use asenapine or pharmaceutically acceptable salt thereof in any form i.e. irrespective of any polymorphic form or amorphous form or combination of any two polymorphic form or combination of amorphous and polymorphic form and without any limitation or of specific particle size as input material for preparation of pharmaceutical composition.
  • the advantage of invented process is that irrespective of any form (i.e. any polymorphic or amorphous with any particle size) of asenapine or pharmaceutically acceptable salt thereof used as input material, in the final pharmaceutical composition asenapine or pharmaceutically acceptable salt thereof would be in amorphous form only.
  • process for preparation of pharmaceutical composition of asenapine or pharmaceutically acceptable salt thereof comprises the step of:
  • step b) granulate the mixture of water soluble diluent(s) and disintegrant(s) with solution of step b) and dry the resulted granules;
  • step c) mix the granules of step c) with one or more pharmaceutically acceptable excipient selected from disintegrant, lubricant, glidant, sweeteners, flavoring agent, coloring agent, antiadherents or mixture thereof and
  • step d) fill the granules of step d) in capsules or compressed in to tablet.
  • granulation can be performed in rapid mixture granulator (RMG) or top spray granulation in Fluid bed processor (FBP)
  • RMG rapid mixture granulator
  • FBP Fluid bed processor
  • organic solvent is selected form, but not limited to dicholormethane, alcohols such as methanol, ethanol, n- propanol, isopropanol, and various isomers of butanol; ketones, such as acetone, methyl ethyl ketone, methyl iso-butyl ketone, and cyclohexanone; esters, such as methyl acetate, ethyl acetate, and propyl acetate; ethers, such as dimethyl ether, tetrahydrofuran, methyl tetrahydrofuran, 1 ,3-dioxolane, and 1 ,4-dioxane; alkanes, such as butane and pentane; alkenes, such as pentene and cyclohexene; nitriles, such as acetonitrile; alkyl halides, such as Dichloromethane (methylene
  • organic solvent is mixture of one or more organic solvent.
  • organic solvent is mixture of dicholormethane or isopropylalcohol.
  • a pharmaceutical composition comprising asenapine or pharmaceutically acceptable salt thereof, antioxidant, water soluble/swellable binder, water soluble diluent, disintegrant and optionally one or more surfactant and/or one or more pharmaceutically acceptable excipient as per the present invention is bioequivalent to marketed product Saphris® /Sycrest®.
  • a pharmaceutical composition comprising asenapine or pharmaceutically acceptable salt thereof, antioxidant, water soluble/swellable binder, water soluble diluent, disintegrant, surfactant and optionally one or more pharmaceutically acceptable excipient as per the present invention is bioequivalent to marketed product Saphris® /Sycrest®.
  • Step b) mix mannitol and low substituted-HPC and load in Fluid bed processor (FBP); c) . spray solution of Step a) on blend of step b) and dry the granules;
  • FBP Fluid bed processor
  • step c) mix the granules of step c) with low substituted-HPC and sodium stearyl fumarate and
  • step d) compress the granules of step d) in to tablet.
  • step c) mix the granules of step c) with low substituted-HPC and sodium stearyl fumarate and
  • step d) compress the granules of step d) in to tablet.
  • step c) mix the granules of step c) with low substituted-HPC and sodium stearyl fumarate and
  • step d) compress the granules of step d) in to tablet.
  • step b) add asenapine or pharmaceutically acceptable salt thereof in solution of step a); c) . granulate mixture of Mannitol and low substituted-HPC with solution of step b) and dry the resulted granules;
  • step c) mix the granules of step c) with low substituted-HPC and sodium stearyl fumarate and
  • step d) compress the granules of step d) in to tablet.
  • step b) add asenapine or pharmaceutically acceptable salt thereof in solution of step a); c) . granulate mixture of mannitol and low substituted-HPC with solution of step b) and dry the resulted granules;
  • step c) mix the granules of step c) with low substituted-HPC and sodium stearyl fumarate and
  • step d) compress the granules of step d) in to tablet.
  • step b) add asenapine maleate in solution of step a); c) . granulate the mixture of mannitol and low substituted-HPC with solution of step b) and dry the resulted granules;
  • step c) mix the granules of step c) with low substituted-HPC and sodium stearyl fumarate and

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/IB2014/062575 2013-06-28 2014-06-25 Stable pharmaceutical composition of asenapine WO2014207664A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2206/MUM/2013 2013-06-28
IN2206MU2013 IN2013MU02206A (enrdf_load_stackoverflow) 2013-06-28 2014-06-25

Publications (2)

Publication Number Publication Date
WO2014207664A2 true WO2014207664A2 (en) 2014-12-31
WO2014207664A3 WO2014207664A3 (en) 2015-04-02

Family

ID=52142775

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/062575 WO2014207664A2 (en) 2013-06-28 2014-06-25 Stable pharmaceutical composition of asenapine

Country Status (2)

Country Link
IN (1) IN2013MU02206A (enrdf_load_stackoverflow)
WO (1) WO2014207664A2 (enrdf_load_stackoverflow)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015125152A3 (en) * 2014-02-18 2015-12-10 Hetero Research Foundation Pharmaceutical compositions of asenapine
US10085971B2 (en) 2016-08-22 2018-10-02 Navinta Iii Inc Pharmaceutical solution of asenapine for sublingual or buccal use
CN109288800A (zh) * 2018-10-30 2019-02-01 天津仁生医药科技有限公司 马来酸阿塞那平片及其制备方法
CN109330984A (zh) * 2018-11-20 2019-02-15 天津仁生医药科技有限公司 一种马来酸阿塞那平舌下片及其制备方法
US10898449B2 (en) 2016-12-20 2021-01-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
WO2021085211A1 (ja) * 2019-10-28 2021-05-06 久光製薬株式会社 アセナピン－ｎ－オキシドの生成を抑制する方法
US11033512B2 (en) 2017-06-26 2021-06-15 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
US11648213B2 (en) 2018-06-20 2023-05-16 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2182981C (en) * 1994-03-02 2006-10-17 Leonardus Petrus Carla Delbressine Sublingual or buccal pharmaceutical composition
WO2012123325A1 (en) * 2011-03-11 2012-09-20 Medichem S.A. NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015125152A3 (en) * 2014-02-18 2015-12-10 Hetero Research Foundation Pharmaceutical compositions of asenapine
US10085971B2 (en) 2016-08-22 2018-10-02 Navinta Iii Inc Pharmaceutical solution of asenapine for sublingual or buccal use
US10898449B2 (en) 2016-12-20 2021-01-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US10980753B2 (en) 2016-12-20 2021-04-20 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US12138353B2 (en) 2016-12-20 2024-11-12 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
US11033512B2 (en) 2017-06-26 2021-06-15 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
US11648213B2 (en) 2018-06-20 2023-05-16 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN109288800A (zh) * 2018-10-30 2019-02-01 天津仁生医药科技有限公司 马来酸阿塞那平片及其制备方法
CN109330984A (zh) * 2018-11-20 2019-02-15 天津仁生医药科技有限公司 一种马来酸阿塞那平舌下片及其制备方法
WO2021085211A1 (ja) * 2019-10-28 2021-05-06 久光製薬株式会社 アセナピン－ｎ－オキシドの生成を抑制する方法
CN114302716A (zh) * 2019-10-28 2022-04-08 久光制药株式会社 抑制阿塞那平-n-氧化物的生成的方法
JPWO2021085211A1 (ja) * 2019-10-28 2021-11-25 久光製薬株式会社 アセナピン−ｎ−オキシドの生成を抑制する方法
US12343329B2 (en) 2019-10-28 2025-07-01 Hisamitsu Pharmaceutical Co., Inc. Method for suppressing production of asenapine-N-oxide

Also Published As

Publication number Publication date
IN2013MU02206A (enrdf_load_stackoverflow) 2015-06-12
WO2014207664A3 (en) 2015-04-02

Similar Documents

Publication Publication Date Title
WO2014207664A2 (en) Stable pharmaceutical composition of asenapine
JP2008532953A5 (enrdf_load_stackoverflow)
WO2015152433A1 (en) Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
NZ576987A (en) Pharmaceutical formulation comprising neurokinin antagonist
CA2683276A1 (en) Ziprasidone formulations
WO2015128877A1 (en) Pharmaceutical compositions of sitagliptin
WO2010111264A2 (en) Rasagiline formulations
US10512619B2 (en) Solid oral formulation of fenretinide
EP3620156A1 (en) Composition having improved water solubility and bioavailability
HK1245646A1 (zh) 口服給藥用醫藥組合物
WO2014167579A2 (en) Stable pharmaceutical compositions of tadalafil
CA3092948A1 (en) Pharmaceutical composition comprising brexpiprazole
US20240415777A1 (en) Instant release pharmaceutical preparation of anticoagulant and preparation method therefor
WO2021220295A1 (en) Immediate release pharmaceutical compositions comprising palbociclib
AU2021337086B2 (en) Solid oral formulation of utidelone
US10406127B2 (en) Solid oral formulation of fenretinide
US20120121700A1 (en) Pharmaceutical formulations comprising valganciclovir
KR100581169B1 (ko) 용해도가 개선된 테르비나핀의 약제조성물 및 그 제조방법
EP4026541A1 (en) A film coated tablet of apixaban
KR20030042504A (ko) 피나스테라이드 경구용 제제 및 그의 제조방법
EP4026540A1 (en) A film coated tablet comprising apixaban
EP3843702A1 (en) Immediate release fixed-dose combination of memantine and donepezil
US20130108701A1 (en) Solid Dosage Forms of Antipsychotics

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 14817924

Country of ref document: EP

Kind code of ref document: A2